Guardant Health Income Statement 2025-2011 | GH

Brief overview of income trends at Guardant Health

The overview follows changes across a five-year period. Guardant Health reported revenue of $287 million in 2020 and $982 million by 2025. The five-year change reached +242.5%, while CAGR stood at 27.9%. Revenue growth reflects a pronounced phase of business expansion.

Over the period, EBITDA shifted from −$239 million to −$398 million, a change of −66.4%. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from −83.3% to −40.5%. The company improved its ability to convert sales into EBITDA.

The final result was −246 million dollars initially and −416 million dollars in the final year. Larger losses indicate rising pressure on the business.

Market capitalization changed from 12.6 billion dollars to 13.4 billion dollars (+6.9%). Valuation expanded much faster than the underlying results.

Summary assessment

The five-year picture requires weighing both strengths and weaknesses. The constructive conclusion rests on a larger revenue base and an improving EBITDA margin. Caution is warranted because of a narrow EBITDA buffer and a weaker final result. Further direction will depend on top-line growth, operating profitability, and net income.